Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn(Délégation Paris 5), Jean-François Delfraissy(Agence Nationale de Recherches sur le Sida et les Hépatites Virales), Ghislaine Leleu(Bristol-Myers Squibb (Germany)), Ágnes Balogh(Bristol-Myers Squibb (Germany)), Vadim Pokrovsky(Central Research Institute of Epidemiology), Adriano Lazzarin(Vita-Salute San Raffaele University), José Sanz, Eric Vandeloise(Bristol-Myers Squibb (Germany)), Santiago Moreno(Universidad El Bosque), Gilles Pialoux, Giampiero Carosi(Institute for Scientific Interchange), Sophie Biguenet(Bristol-Myers Squibb (Germany))
Cited by 39
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
|The Lancet|1999|667
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653